Exelixis
Develops and commercializes cancer medicines around cabozantinib and a broader oncology pipeline.
$54.00
After-hours close−0.42 (−0.77%)
At close$54.42(−1.52%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 109.83%Insiders 3.96%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 251.36M · Float 204.46M · 81.3% free float
Institutions13F, as of Jun 30, 2026
775 holders · 276.06M shares · 137 new positions · 392 increased · 281 reduced · 80 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 29.08M | 11.57% | −1.74M | Aug 7, 2026 |
| Farallon Capital Management LLC | 13.47M | 5.36% | +357.0K | Aug 14, 2026 |
| Renaissance Technologies LLC | 13.43M | 5.34% | −299.0K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 12.04M | 4.79% | −42.2K | Aug 13, 2026 |
| AQR Capital Management LLC | 11.02M | 4.39% | −2.07M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 10.95M | 4.36% | −308.0K | Aug 13, 2026 |
| State Street Corp | 9.97M | 3.97% | −328.4K | Aug 7, 2026 |
| Fuller & Thaler Asset Management, Inc. | 8.93M | 3.55% | +387.2K | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.20% | 28.50M | 13G | Apr 28, 2025 ↗ |
| Farallon Capital Management, L.L.C.incl. Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P. +26 more | 5.60% | 13.99M | 13D | Aug 14, 2026 ↗ |
| Vanguard Capital Management | 5.09% | 13.23M | 13G | Apr 29, 2026 ↗ |
| AQR Capital Management, LLC | 5.09% | 13.66M | 13G | Feb 13, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Michael Morrissey | director, officer: President and CEO | 3.37M | 1.34% | May 19, 2026 |
| David Edward Johnson | director | 1.55M | 0.62% | Nov 26, 2025 |
| Stelios Papadopoulos | director | 1.20M | 0.48% | May 29, 2026 |
| Christopher J. Senner | officer: EVP and CFO | 952.3K | 0.38% | May 19, 2026 |
| Jeffrey Hessekiel | officer: EVP & General Counsel | 693.4K | 0.28% | May 16, 2025 |
| Dana Aftab | officer: EVP, Research and Development | 594.7K | 0.24% | May 28, 2026 |
| Amy C. Peterson | officer: EVP Prod Dev & Med Aff & CMO | 465.4K | 0.19% | May 16, 2025 |
| Patrick J. Haley | officer: EVP, Commercial | 357.6K | 0.14% | May 22, 2026 |
| Jack L. Wyszomierski | director | 284.4K | 0.11% | Jun 3, 2026 |
| George Poste | director | 127.2K | 0.05% | May 29, 2026 |
1 ten-percent owner holds 7.9K shares by Form 4, outside the officers-and-directors figure above · 18 people have not refiled in the last 18 months (4.66M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 10, 2026 | Mary C. Beckerledirector | Sale | 9,812 | $53.66 | 16,079 |
| Jun 1, 2026 | Sue Gail Eckhardtdirector | Sale | 9,812 | $50.14 | 16,079 |
| Jun 1, 2026 | Jack L. Wyszomierskidirector | Sale | 3,925 | $50.55 | 284,384 |
| May 26, 2026 | Dana Aftabofficer: EVP, Research and Development | Sale | 43,451 | $50.35 | 594,741 |
| May 20, 2026 | Patrick J. Haleyofficer: EVP, Commercial | Sale | 32,110 | $49.81 | 357,638 |
| May 18, 2026 | Brenda Heftiofficer: SVP and General Counsel | Sale | 6,625 | $50.21 | 106,762 |
| May 18, 2026 | Christopher J. Sennerofficer: EVP and CFO | Sale | 34,901 | $50.00 | 952,317 |
| May 7, 2026 | George Postedirector | Sale | 60,000 | $45.71 | 118,832 |
| May 7, 2026 | Maria C. Freiredirector | Sale | 20,634 | $46.00 | 100,819 |
| May 7, 2026 | Mary C. Beckerledirector | Sale | 7,712 | $48.45 | 17,524 |
CongressHouse and Senate disclosures
Not reported.